Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan

Keyphrases

• Erythematosus 100%
• Belimumab 100%
• Statistical Analysis Plan 100%
• B Cell Depletion Therapy 100%
• Rituximab 66%
• Placebo 33%
• Systemic Lupus Erythematosus 33%
• Clinical Follow-up 33%
• Concomitant Medications 33%
• Quality of Life 16%
• Adverse Events 16%
• Phase II Trial 16%
• Randomized Double-blind 16%
• Effective Treatment 16%
• Treatment Effect 16%
• Missing Data 16%
• Clinical Setting 16%
• Absence of Evidence 16%
• Sample Size Calculation 16%
• Modeling Strategy 16%
• Anti-DNA Antibodies 16%
• Lupus Flare 16%
• Post-randomization 16%
• Trial Registration 16%
• B-cell Depletion 16%
• Rituximab Therapy 16%
• Lupus Damage 16%
• EudraCT 16%
• Clinical Biomarkers 16%
• Medication Dosing 16%

Medicine and Dentistry

• B Cell 100%
• Belimumab 100%
• Rituximab 83%
• Placebo 33%
• Systemic Lupus Erythematosus 33%
• Clinical Trial 16%
• Lupus Erythematosus 16%
• Biological Marker 16%
• Quality of Life 16%
• Adverse Event 16%
• Treatment Effect 16%
• Phase II Trials 16%
• Anti-dsDNA Antibodies 16%
• Statistical Modeling 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Belimumab 100%
• Rituximab 83%
• Placebo 33%
• Systemic Lupus Erythematosus 33%
• Clinical Trial 16%
• Adverse Event 16%
• Biological Marker 16%
• Phase II Trials 16%
• Statistical Modeling 16%